



Dear reader of Biopeople's November Newsletter

Please find below links to news and articles on various issues, which we consider interesting for the Danish life science community. One of the articles deals with a most important subject, paediatric clinical trials. Many drugs are used for children off-label because they have never been tested in children. Danish researchers at Rigshospitalet do their best to change that.

EMA will not relocate to Denmark but to Holland, which may be of importance to a future Danish life science industry. Biopeople, however, has good relations to Dutch life science and EMA'S presence might be a strengthening factor for the national relations within the industry.

Last but not least I want to inform you that I will leave Biopeople as per 1 December 2017 to take up a new position outside the university. I thank you so much for the collaboration over the last years.

For comments, inquiries or other regarding the newsletter, website etc. please contact Per Spindler, pesp@biopeople.ku.dk

Enjoy your reading

Warm regards
Randi Krogsgaard



Biopeople welcomes the decision by the 27 EU Member States to move the European Medicines Agency (EMA) from London to Amsterdam. EMA is a key regulatory agency for our single market and is essential for the authorization and control of medicines

> [READ MORE](#)



BioFactory consortium hosts a conference on 6. February 2018 at Axelborg, Copenhagen. The conference theme is the commercial perspectives



for the use of active ingredients in plants for medicine, health care and food.

[> READ MORE \(IN DANISH\)](#)



Off-label use of drugs used for anaesthesia and treatment of pain in children is an accepted practice considered superior to the alternative of withholding needed medications. According to Bettina Nygaard Nielsen, Ph.D.clinical pharmacist and a part of the Paediatric Research Team at the Department of Anaesthesiology, Juliane Marie Centre, Rigshospitalet, University of Copenhagen (photo), there is still much to do to determine efficacy and safety of drugs that lack labelling for children who is a vulnerable group of patients.

[> READ MORE](#)



In October this year we accomplished a share issue which was heavily oversubscribed. This reflected a high interest for 2cureX, which was founded in 2006 with the vision of improving treatment efficiency of cancer patients.

[> READ MORE](#)



DKK 13,38 million for a new Danish Research Infrastructure for the benefit of Danish research in infectious diseases, multi resistant bacteria and development of new therapies against chronic diseases.

[> READ MORE IN DANISH](#)



Thanks to everyone for making the 2017 Biomarker AGORA a fantastic event. More than 300 people, i.e. researchers from the Universities of Copenhagen, Aalborg and Southern Denmark, people from Danish and Swedish SME's, students & graduates, patient organisations, funding organisations and regions joined to participate in this untraditional matchmaking event.

> [READ MORE](#)



[Check Biopeople's Calendar for upcoming events](#) - coming up is a meeting on Funding Opportunities for medtech and biotech. (Follow link)

We publish events we host and/or co-ordinate and also other relevant events for the life science community, so please do not hesitate to contact us if you host an event and want to promote it at <https://Biopeople.eu>

Biopeople contact

Per Spindler pesp@biopeople.ku.dk

> [JOIN THE MEETING ON FUNDI...](#)